CYDY has reverted to the 2019 version of itself, when HIV was the main indication with cancer and NASH as possible indications. Big difference is that 2019 CYDY didn’t have a pending SEC/DOJ investigation, owe $30 million in past due payments to Samsung, $15 million past due to Amarex and arbitration, a pending shareholder lawsuit, AND nearly twice as many outstanding shares with a dwindling amount available to raise funds. As the acting President of CYDY said today, CYDY has challenges that will shape the immediate future.
SK finally admitted today that the cancer data CYDY has isn’t enough to support a BTD. I’ve been saying that for almost a year as NP pumped a BTD on only 28 patients. Idiot should’ve kept Dr. Jay happy and the trials enrolling.
From the 8ks, there appears to be one “accredited investor” funding CYDY from month to month. Let’s see if he coughs up another million after the trial halt by the FDA. His most recent shares are already upside down by 20%.
Should be an interesting April.
Market Data 
Markets 
